drugset
drugset / Trial / NCT00522249

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

NCT00522249 ↗

Phase 1/2 Terminated 10 enrolled The Methodist Hospital Research Institute Schering-Plough · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study will determine the best dose of Peg-Intron, Sunitinib and Tarceva when given in combination. The safety of giving these drugs in combination and response to treatment will also be examined.

Timeline

Start
2007-05
Primary completion
2008-05
Completion
2008-07

Outcome

Outcome not reported

Stopped: “PI decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral
Subject Pegylated Alfa Interferon Unknown — Subcutaneous
Subject Sunitinib Small molecule — Oral

Indications

renal cell carcinoma